Precision medicine helps to narrow the universe of patients down to the segment of patients in which that specific therapy will have a positive strong response while minimizing the risk of serious and adverse side effects.

Step 1: In the most simplified of manners, the first step in this process is identifying the segment of the universe that will respond to therapy.

Step 2: The next step is identifying the segments that are likely to have mild, serious or adverse side effects.

Step 3: The teams will then use this information to identify the segment that will have a strong response to a therapy without having serious or adverse side effects

Obviously, this is a rather oversimplified approach to stratification of populations for therapeutic targeting – however the value of doing this kind of stratification is immense.

As more biopharma companies seek approval for high-cost oncology therapies valued upwards of $100,000 – more and more payors will be seeking more healthcare outcomes data in order to define reimbursement strategies.